Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stage IV childhood renal tumor trial comparing upfront VAD versus VCE
2018-000533-13Phase 3Active
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jun 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, actinomycin D, doxorubicin, carboplatin and etoposide in Nephroma and Wilms' tumor (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Overall metastatic response rate after 6 weeks of preoperative chemotherapy. Started Jun 2018; status: active.
02
Drugs
vincristineactinomycin Ddoxorubicincarboplatinetoposide
03
Conditions
NephromaWilms' tumor
Beyond the preview
Go deeper on 2018-000533-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000533-13.